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Introduction
It is considered that the severity of CIPs with LLSt is
higher than the overall CIPs requiring ICU admission.
The identification of specific clinical variables which
determine the severity of the CIPs with LLST perhaps
has not been researched enough.
Objectives
• To asses the severity of the CIPs with LLST in
comparison to CIPs with LLS.
• To evaluate and compare the mortality between
two populations.
Methods
• Type of study: prospective, analytical, longitudinal,
and observational
• Period: January 1-2011 / June 30-2014 (42 months)
• Setting : Medical / Surgical ICU
• Population: 2559 CIPs admitted consecutively to
the ICU; sample: 220 CIPs with LLST.
• Exclusión criteria: CIPs < 16 y., major burn CIPs,





c) Case - mix: severe sepsis, metabolic acidosis, total par-
enteral nutrition (TPN), oncological pathology, intra-
abdominal pressure (IAP), blood products, cultures, car-
diac continous output (CCO), advanced life support (ALS)
before LLTS applied, FGC, FBC.
• Statistical analysis: Ji squared and contrast of
means (Student’s t)
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Table 1. Results 1
Global % - SD LLST % - SD without LLST % - SD p value
CIPs 2559 100 220 8,6 2339 91,4 0,0001
Age 65,9 16,7 77,2 10,6 64,8 16,8 0,0001
Mortality 182 7,1 115 52,3 67 2,96 0,0001
Sepsis 484 18,9 122 55,4 362 15,4 0,0001
Metabolic acid. 955 37,3 155 70,4 800 34,2 0,0001
oncol. pathology 903 35,3 84 38,2 819 35,0 NS
TPN 467 18,27 72 32,7 395 16,8 0,0001
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Results
See tables 1 and 2.
Conclusions
• More than 50 % of CIPs with LLST die.
• According to all clinical variables, SS, metabolic
acidosis, TPN, IAP, blood products, cultures, ALS,
FGC, FBC, and cardiac output are much higher in
CIPs with LLST.
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Table 2. Results II
Global % - SD LLST % - SD without LLST % - SD p value
IAP 136 5,3 51 23,1 85 3,63 0,0001
Blood products 500 19,5 99 45,0 401 17,1 0,0001
Cultures 689 26,9 144 65,4 545 23,3 0,0001
ALS 85 3,32 16 7,3 69 2,9 0,0001
FGC 54 2,1 21 9,5 33 1,4 0,0001
FBC 61 2,4 24 10,9 37 1,6 0,0001
CCO 114 4,4 46 20,9 68 2,9 0,0001
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